Skip to main content
Navamedic logo

Navamedic — Investor Relations & Filings

Ticker · NAVA ISIN · NO0010205966 LEI · 529900LKVQOR2SRUJU71 OL Wholesale and retail trade
Open in API
Filings indexed 825 across all filing types
Latest filing 2019-05-15 Earnings Release
Country NO Norway
Listing OL NAVA

About Navamedic

https://navamedic.com/

Navamedic is a pharmaceutical company that develops, produces, and commercializes a diverse portfolio of medicines and related health products. The company's offerings include specialty pharmaceuticals, branded generics, and consumer health items. Its product portfolio addresses various medical needs, with treatments for conditions such as obesity, Parkinson's disorder, and inborn errors of metabolism, in addition to antibiotics. Serving as a reliable supplier and distribution partner, Navamedic provides high-quality products to hospitals and pharmacies, with a strong presence in the Nordic region and the Netherlands. The company focuses on improving patient outcomes through innovations, including advancements in personalized treatment for Parkinson's care.

Recent filings

Filing Released Lang Actions
Navamedic ASA: Q1 2019 financial results
Earnings Release Classification · 100% confidence The document explicitly states it contains the 'Q1 2019 financial results' for Navamedic ASA. It details key financial metrics for the first quarter (revenues, EBITDA, gross margin) and includes commentary from the CEO regarding performance and strategy. This structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, focusing on key highlights rather than the comprehensive detail found in a full Interim Report (IR). Since the document is short and focuses on announcing the period's performance, ER is the most appropriate classification. Q1 2019
2019-05-15 English
Navamedic ASA: Resultater for første kvartal 2019
Investor Presentation Classification · 99% confidence The document is titled "First quarter results 2019 Navamedic ASA" and contains detailed financial tables for Q1 2019 compared to Q1 2018, including income statements, balance sheets, and cash flow statements. It also includes operational highlights, segment analysis, and a summary/outlook section. This structure is characteristic of a comprehensive financial report covering a period shorter than a full year. Therefore, it fits the definition of an Interim / Quarterly Report (IR). It is not merely an Earnings Release (ER) as it contains extensive balance sheet and cash flow details, nor is it the Annual Report (10-K).
2019-05-15 English
Navamedic ASA: Resultater for første kvartal 2019
Earnings Release Classification · 100% confidence The document is titled "Navamedic ASA: Resultater for første kvartal 2019" (Results for the first quarter 2019) and contains key financial metrics (operating revenue, EBITDA) and management commentary specific to the first quarter. This clearly indicates it is a report detailing financial performance for a period shorter than a year (Q1 2019). This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). It is not a full Annual Report (10-K), nor is it merely an announcement of a report (RPA), as it contains the actual results. Q1 2019
2019-05-15 Norwegian
Navamedic ASA: Q1 2019 financial results
Earnings Release Classification · 100% confidence The document explicitly states it contains the 'Q1 2019 financial results' for Navamedic ASA. It details key financial metrics for the first quarter (revenues, EBITDA, gross margin) and includes commentary from the CEO regarding performance and strategy. This structure is characteristic of an Earnings Release (ER), which provides the initial announcement of periodical financial results, focusing on key highlights rather than the comprehensive detail found in a full Interim Report (IR). Since the document is short and focuses on announcing the period's performance, ER is the most appropriate classification. Q1 2019
2019-05-15 English
Navamedic ASA: Resultater for første kvartal 2019
Earnings Release Classification · 100% confidence The document is titled "Navamedic ASA: Resultater for første kvartal 2019" (Results for the first quarter 2019) and contains key financial metrics (operating revenue, EBITDA) and management commentary specific to the first quarter. This clearly indicates it is a report detailing financial performance for a period shorter than a year (Q1 2019). This aligns perfectly with the definition of an Interim / Quarterly Report (Code: IR). It is not a full Annual Report (10-K), nor is it merely an announcement of a report (RPA), as it contains the actual results. Q1 2019
2019-05-15 Norwegian
Navamedic ASA: Proposes IPO for Medtech division
Share Issue/Capital Change Classification · 99% confidence The document announces the Board of Directors' proposal to separately list the Medtech division (commercializing Sippi) on the Oslo Stock Exchange in Q3 2019, requiring an Extraordinary General Assembly. This action involves a significant change in the company's capital structure and corporate organization, specifically related to a spin-off/listing event. This fits best under 'Capital/Financing Update' (CAP) as it details a major financing/structural activity intended to maximize value creation, rather than a standard M&A (TAR) or a simple share repurchase (POS). It is not a standard regulatory report (10-K, IR, ER) or a meeting announcement (AGM-R, DEF 14A).
2019-05-14 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.